Kisspeptin

Kisspeptin sits at the very top of the reproductive hormone axis, triggering the brain's release of GnRH and, downstream, testosterone or estrogen. It's studied mainly for its role in fertility treatment and hormone signaling. It's a natural neuropeptide, most often studied as the 54-amino-acid kisspeptin-54 or the shorter kisspeptin-10. It's not FDA-approved for any indication and is investigational only; outside academic trials, it's sold as a research chemical.

Kisspeptin has been studied mainly in fertility treatment — as a gentler way to trigger egg maturation during IVF — and investigated for its role in the reproductive-hormone axis, including libido and restarting the body's own hormone production. In a 2015 Phase II trial, a single dose of kisspeptin-54 matured eggs for IVF in women at high risk of ovarian hyperstimulation syndrome (OHSS), with zero moderate-to-severe cases of that complication. The libido and hormone-recovery uses rest on extrapolation rather than direct trial evidence. It is investigational only and not FDA-approved.

Not FDA-approved for any indication. Kisspeptin (in both kisspeptin-54 and kisspeptin-10 forms) is investigational only — no national regulator has approved any kisspeptin formulation for any clinical indication. The most clinically-advanced kisspeptin program is the Imperial College London / Dhillo group kisspeptin-54 IVF-trigger Phase II program — the Abbara 2015 *J Clin Endocrinol Metab* phase 2 multi-dose open-label RCT demonstrated that kisspeptin-54 can effectively and safely trigger oocyte maturation in IVF patients at high risk of ovarian hyperstimulation syndrome (OHSS) — with 0 cases of moderate, severe, or critical OHSS across 60 women.[³] Available outside the academic-clinical-trial context exclusively as a research peptide through unregulated research-peptide supply chains. Not DEA-scheduled. ⚠️ WADA-banned in male athletes — kisspeptin is explicitly named in the WADA 2026 Prohibited List under S2.2.1 (Testosterone-stimulating peptides in males): "kisspeptin and its agonist analogues", alongside chorionic gonadotrophin (CG), luteinizing hormone (LH), and GnRH (gonadorelin). Prohibited at all times, in males. The listing is explicit and sits under S2.2.1 (testosterone-stimulating peptides), not S2.3 (growth factors) — confirmed directly against the archived 2026 list.

Kisspeptin is not FDA-approved for any indication, is investigational, and its long-term safety with repeated dosing is essentially uncharacterized; it is banned in male athletes under WADA rules. VialWise is a research and educational reference, not medical advice — consult a licensed professional.

⚠️ For research and educational purposes only. Kisspeptin (kisspeptin-54 and kisspeptin-10 forms) is not approved by the FDA for any indication and is not approved by any national regulator anywhere in the world. The most clinically-advanced kisspeptin program is the Imperial College London / Dhillo group academic kisspeptin-54 IVF-trigger Phase II program; this work is investigational only. Kisspeptin is available outside academic clinical trials exclusively as a research peptide through unregulated supply chains. Information in this entry is informational, not medical advice. Always confirm dose calculations with the in-app calculator and consult appropriate professional guidance before any protocol decisions.

⚠️ Kisspeptin operates on a different endocrine axis from the GHS-axis library entries. Unlike the GHRP-class peptides (Ipamorelin, Hexarelin, GHRP-2, GHRP-6, MK-677) and the GHRH analogs (Sermorelin, CJC-1295, Tesamorelin) that act on the somatotropic (GH/IGF-1) axis, kisspeptin acts on the hypothalamic-pituitary-gonadal (HPG) axis — kisspeptin stimulates GnRH release from hypothalamic GnRH neurons, which triggers downstream LH and FSH release from the anterior pituitary, which drives gonadal sex-steroid (testosterone in males, estradiol/progesterone in females) synthesis. Cluster context: kisspeptin sits in the HPG-axis cluster alongside HCG, Gonadorelin (GnRH analog), PT-141 (melanocortin axis with HPG-axis effects), and the aromatase-inhibitor / SERM compounds (Anastrozole, Letrozole, Exemestane, Clomiphene, Tamoxifen). For library navigation: research-community use cases for kisspeptin overlap with but are distinct from the use cases for the GHS-axis cluster.

⚠️ The most clinically-relevant kisspeptin finding is the OHSS-prevention IVF-trigger work (Abbara 2015 JCEM). In a phase 2 multi-dose open-label RCT of 60 women undergoing IVF at high risk of ovarian hyperstimulation syndrome, kisspeptin-54 as the ovulation trigger produced 95% oocyte maturation and 45% live birth rate per embryo transfer, with zero cases of moderate, severe, or critical OHSS — even at the highest kisspeptin-54 dose (12.8 nmol/kg).[³] This compares favorably to the traditional hCG trigger which can cause OHSS in high-risk patients. Kisspeptin-54 IVF trigger is the most-clinically-advanced kisspeptin application and is the clinical use case anchoring the entry's clinical relevance. The Imperial College London / Dhillo group has published multiple follow-on studies extending this finding.

⚠️ Kisspeptin-54 has substantially longer effective duration than kisspeptin-10 — and the two are not interchangeable. Per the published Imperial College London / Dhillo group clinical pharmacology, kisspeptin-10 has a plasma half-life of approximately 4 minutes (rapidly cleared), while kisspeptin-54 has a longer effective duration of approximately 25 minutes. The kisspeptin-54 IVF-trigger studies use a single subcutaneous bolus dose; the kisspeptin-10 studies typically use IV bolus or short IV infusion. Research-community use must specify which form is being used — they are not pharmacologically interchangeable.

⚠️ WADA-banned in male athletes — kisspeptin is explicitly named in the WADA 2026 Prohibited List under Section S2.2.1 (Testosterone-stimulating peptides in males): "kisspeptin and its agonist analogues", listed alongside chorionic gonadotrophin (CG), luteinizing hormone (LH), and GnRH (gonadorelin). Prohibited at all times, in males. The listing is explicit and sits under S2.2.1, not S2.3 — confirmed directly against the archived 2026 list. Users in regulated sport should treat kisspeptin as prohibited and confirm against the current annual edition before any competitive event.

According to PubMed-indexed research, kisspeptin is an endogenous neuropeptide encoded by the KISS1 gene that acts as a critical upstream regulator of the hypothalamic-pituitary-gonadal (HPG) axis.[²][⁴][⁵] The full-length KISS1 precursor is 145 amino acids; proteolytic processing produces several bioactive C-terminal fragments including kisspeptin-54 (the most-studied therapeutic form), kisspeptin-14, kisspeptin-13, and kisspeptin-10 (the C-terminal decapeptide). All bioactive fragments share the C-terminal sequence that binds to the KISS1R receptor (also known as GPR54 in the older literature). The KISS1R receptor is a G-protein-coupled receptor expressed primarily on hypothalamic GnRH neurons — kisspeptin/KISS1R signaling triggers GnRH release, which then triggers LH and FSH release from the anterior pituitary, which then drives gonadal sex-steroid synthesis.

Discovery history. KISS1 was originally identified in the late 1990s as a metastasis-suppressor gene (hence the historical name "metastin") expressed at varying levels across human cancers. The reproductive-endocrinology function was characterized in 2003 by the Seminara group at Massachusetts General Hospital in a landmark *New England Journal of Medicine* paper.[²] The Seminara 2003 study identified loss-of-function GPR54 mutations (L148S, R331X, X399R) in consanguineous-family patients with idiopathic hypogonadotropic hypogonadism (IHH) — autosomal-recessive inheritance with the GnRH-axis-deficiency phenotype. A parallel Gpr54-knockout mouse model produced the same phenotype: small testes in males, delayed vaginal opening and absence of follicular maturation in females. Critically, the GPR54-deficient mice responded normally to exogenous GnRH — establishing that the defect was upstream of GnRH release, not at the GnRH-receptor or pituitary level. This identified kisspeptin/GPR54 signaling as the gatekeeper of pubertal onset and normal HPG-axis function — one of the most-cited reproductive-endocrinology discoveries of the 2000s.[²][⁴][⁵]

The "gatekeeper of puberty" thread.[²][⁴][⁵] The Seminara 2003 finding established that kisspeptin/KISS1R signaling is essential for normal pubertal HPG-axis activation. Subsequent work — reviewed in the Seminara 2005 *Frontiers in Neuroendocrinology* paper[⁴] and the Gianetti/Seminara 2008 *Reproduction* review[⁵] — established the full kisspeptin/KISS1R reproductive-physiology framework: (a) developmental changes in kisspeptin expression support its critical role in the pubertal transition; (b) kisspeptin is a powerful stimulus of GnRH-induced gonadotropin secretion; (c) kisspeptin modulates both positive and negative sex-steroid feedback effects at the hypothalamic level; (d) loss-of-function KISS1R mutations cause IHH; (e) gain-of-function KISS1R mutations cause precocious puberty. Kisspeptin is the master regulator of the GnRH pulse generator in normal physiology.

Kisspeptin-54 IVF trigger Phase II program (Abbara 2015 / Imperial College London / Dhillo group).[³] The most clinically-advanced kisspeptin application is the use of kisspeptin-54 as an alternative to hCG for triggering oocyte maturation during IVF treatment in patients at high risk of ovarian hyperstimulation syndrome (OHSS). Traditional hCG triggers can produce sustained LH-like signaling (hCG has a substantially longer plasma half-life than endogenous LH), which can over-stimulate the corpus luteum and produce OHSS — a potentially life-threatening complication. Kisspeptin-54 produces a shorter, more physiological LH-axis activation by triggering endogenous GnRH release, which produces a more physiological LH surge. The Abbara 2015 phase 2 multi-dose open-label RCT enrolled 60 women undergoing IVF at high risk of OHSS at the Hammersmith Hospital IVF unit, London, UK, during 2013–2014. Following a standard recombinant-FSH/GnRH-antagonist protocol, patients were randomly assigned to a single SC kisspeptin-54 trigger at 3.2 / 6.4 / 9.6 / 12.8 nmol/kg (adaptive dose allocation). Oocyte maturation: 95% across all patients. Pregnancy rates per transfer: 63% biochemical, 53% clinical, 45% live birth. Zero cases of moderate, severe, or critical OHSS. Highest oocyte yield (121%) at 12.8 nmol/kg; highest pregnancy rates at 9.6 nmol/kg.[³] The kisspeptin-54 IVF-trigger application is the most clinically-relevant published evidence in the kisspeptin literature.

Mechanism. Based on articles retrieved from PubMed, kisspeptin acts as an agonist at the KISS1R receptor expressed on hypothalamic GnRH neurons.[²][⁴][⁵] KISS1R is a Gq-coupled GPCR; activation produces phospholipase C-mediated inositol triphosphate and diacylglycerol generation, intracellular calcium mobilization, and downstream GnRH release into the hypothalamic-pituitary portal circulation. Kisspeptin is the upstream activator of the GnRH pulse generator — it does not directly stimulate LH or FSH release from the pituitary (that requires GnRH receptor activation at the gonadotrope level). The clinical implication: kisspeptin therapy produces a more physiological HPG-axis stimulation than direct GnRH analog (sermorelin-class), LH analog (hCG-class), or pituitary-bypass approaches.

Common research interests. Kisspeptin is used in research-community contexts for: - IVF ovulation trigger in OHSS-risk patients — the most clinically-advanced application, exclusively in academic clinical-trial context per the Abbara 2015 Phase II program.[³] - HPG-axis stimulation testing (clinical-investigation context) — using kisspeptin-10 IV bolus or short infusion to assess endogenous HPG-axis responsiveness. This is a specialist endocrine-research use case. - Putative libido / sexual-function enhancement — research-community use case extrapolating from kisspeptin's role in normal reproductive physiology; limited published evidence supports this specific application though Comninos 2017 *J Clin Invest* and related Dhillo-group work has explored kisspeptin's effects on sexual-arousal brain-imaging. - Putative HPG-axis recovery after testosterone or AAS cycles — research-community use case extrapolating from kisspeptin's upstream-of-GnRH position; the rationale parallels gonadorelin and HCG use in post-cycle therapy, though the published evidence base is essentially absent.

Regulatory status (US — current). Kisspeptin is not FDA-approved for any indication. No national regulator has approved any kisspeptin formulation for any clinical indication anywhere in the world. The compound is available outside academic clinical trials exclusively as a research peptide through unregulated research-peptide supply chains; not legally compoundable through US 503A pharmacies (the compound is not on the 503A bulks list). Not DEA-scheduled.

Regulatory status (sport — WADA). ⚠️ Kisspeptin IS explicitly named in the WADA 2026 Prohibited List under Section S2.2.1 (Testosterone-stimulating peptides in males) — verbatim "kisspeptin and its agonist analogues", listed alongside chorionic gonadotrophin (CG), luteinizing hormone (LH), and GnRH (gonadorelin). Prohibited at all times, in male athletes. Confirmed directly against the archived 2026 list: the listing is explicit and sits under S2.2.1 (testosterone-stimulating peptides), not S2.3 (growth factors). Users in regulated sport should treat kisspeptin as prohibited and confirm against the current annual edition before any competitive event.

Commonly reported

• Mild injection-site reactions — typical of subcutaneous peptide injection
• Transient mild flushing — reported in some kisspeptin clinical studies
• Headache — reported in some kisspeptin clinical studies, typically mild
• Subjective effects on libido, mood, or energy — reported in research-community use; not well-characterized in published evidence
• Mild gastrointestinal symptoms — reported in some kisspeptin clinical studies
• Sleep-cycle changes — reported by some researchers; not well-characterized
• Long-term safety in adults using kisspeptin off-label is essentially uncharacterized. The Abbara 2015 IVF-trigger Phase II dataset is a single-dose-administration context;[³] chronic-daily-dosing safety in adults is not characterized in published literature.
• The KISS1 gene's original identification as a metastasis-suppressor gene raises a theoretical concern about chronic pharmacological kisspeptin administration in patients with active or remote cancer history. The biology is complex — endogenous kisspeptin signaling is broadly tumor-suppressive in some contexts but pro-proliferative in others — and published evidence does not establish a clear safety signal in either direction.
• HPG-axis stimulation in male users can produce significant estradiol elevation as a downstream consequence of testosterone aromatization. Estradiol monitoring is the load-bearing safety consideration for male research-community use.

Serious

• Significant ovarian hyperstimulation symptoms (abdominal distension, severe pelvic pain, decreased urine output, shortness of breath) in female users — the central rationale for kisspeptin-54's IVF-trigger development was OHSS prevention, but high-dose use in non-clinical-trial settings could still theoretically produce OHSS in susceptible patients; immediate medical evaluation warranted
• Acute mastalgia or new breast lump in male users — significant HPG-axis activation can produce gynecomastia-precursor symptoms; warrants medical evaluation
• Severe headache with visual changes — could suggest pituitary pathology under HPG-axis stimulation; rare but warrants immediate medical evaluation
• Severe or persistent injection-site reaction (induration, abscess, signs of infection) — warrants medical evaluation
• Allergic reaction (hives, swelling, difficulty breathing) — extremely rare but warrants immediate medical evaluation

Active hormone-sensitive cancer (breast, prostate, ovarian, endometrial) — HPG-axis activation may be contraindicated

Pregnancy — no human data outside the IVF-trigger context (where kisspeptin-54 is the trigger before fertilization, not during pregnancy)

Lactation — no human data; default to contraindicated

Pediatric use — no clinical-trial evidence base; default to contraindicated (kisspeptin's role in pubertal onset means pharmacological administration in pediatric patients is theoretically high-impact and not validated by trial evidence)

Active pituitary tumor — caution given upstream HPG-axis activation

Active hyperprolactinemia — caution; HPG-axis stimulation may interact with prolactin-axis pathology

Active malignancy with unclear hormone sensitivity — caution given the metastasis-suppressor original identification of KISS1

Regulatory note (US): Kisspeptin is not FDA-approved for any indication and is not legally compoundable through US 503A pharmacies.

Regulatory note (sport): ⚠️ WADA-banned in male athletes — explicitly named in S2.2.1 (Testosterone-stimulating peptides in males), "kisspeptin and its agonist analogues." Prohibited at all times. (Corrected 2026-05-30 — earlier text wrongly said "uncertain / S2.3"; verified against the archived 2026 list.)

Not DEA-scheduled.

Peptide

A short chain of amino acids, the building blocks of proteins. Many compounds in this library are peptides.

GnRH

Gonadotropin-releasing hormone, the brain signal that tells the pituitary to release the hormones (LH and FSH) controlling testosterone, estrogen, and fertility.

Subcutaneous

An injection into the fatty layer just under the skin, rather than into a muscle or vein.

Testosterone

The principal male sex hormone, important for sexual development, muscle and bone, and other functions.

1. Lee JH, Miele ME, Hicks DJ, Phillips KK, Trent JM, Weissman BE, Welch DR. (1996). KiSS-1, a novel human malignant melanoma metastasis-suppressor gene. Journal of the National Cancer Institute, 88(23):1731–1737 (December 4, 1996).(PMID 8944003)
2. Seminara SB, Messager S, Chatzidaki EE, Thresher RR, Acierno JS Jr, Shagoury JK, Bo-Abbas Y, Kuohung W, Schwinof KM, Hendrick AG, Zahn D, Dixon J, Kaiser UB, Slaugenhaupt SA, Gusella JF, O'Rahilly S, Carlton MB, Crowley WF Jr, Aparicio SA, Colledge WH. (2003). The GPR54 gene as a regulator of puberty. The New England Journal of Medicine, 349(17):1614–1627 (October 23, 2003).(PMID 14573733)
3. Abbara A, Jayasena CN, Christopoulos G, Narayanaswamy S, Izzi-Engbeaya C, Nijher GM, Comninos AN, Peters D, Buckley A, Ratnasabapathy R, Prague JK, Salim R, Lavery SA, Bloom SR, Szigeti M, Ashby DA, Trew GH, Dhillo WS. (2015). Efficacy of Kisspeptin-54 to Trigger Oocyte Maturation in Women at High Risk of Ovarian Hyperstimulation Syndrome (OHSS) During In Vitro Fertilization (IVF) Therapy. The Journal of Clinical Endocrinology & Metabolism, 100(9):3322–3331 (July 20, 2015).(PMID 26192876)
4. Seminara SB. (2005). Metastin and its G protein-coupled receptor, GPR54: critical pathway modulating GnRH secretion. Frontiers in Neuroendocrinology, 26(3-4):131–138 (November 23, 2005).(PMID 16309735)
5. Gianetti E, Seminara S. (2008). Kisspeptin and KISS1R: a critical pathway in the reproductive system. Reproduction (Cambridge, England), 136(3):295–301 (May 30, 2008).(PMID 18515314)

• Gonadorelin — discussed together in this entry's stacks section
• Testosterone — discussed together in this entry's stacks section
• HCG (Human Chorionic Gonadotropin) — same mechanism class
• Clomiphene / Enclomiphene — shared research area
• Melanotan II — shared research area
• PT-141 (Bremelanotide) — shared research area